ArticleAdvances in orthopedics2025
Is Umbilical Cord-Derived Platelet-Rich Plasma a Valid Alternative to Conventional Orthobiologics Post-Knee Arthroscopy?
Article in Advances in orthopedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Is Umbilical Cord-Derived Platelet-Rich Plasma a Valid Alternative to Conventional Orthobiologics Post-Knee Arthroscopy?Advances in orthopedics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Orthobiologic treatments such as autologous platelet-rich plasma (A-PRP) and mesenchymal stem cells (MSCs) are widely used for knee osteoarthritis (OA). Umbilical cord-derived PRP (UCD-PRP), with its standardized composition and high growth factor content, has emerged as a promising allogeneic alternative, though comparative data are limited. Purpose: To compare the short-term clinical outcomes of UCD-PRP versus adipose tissue-derived MSCs (ADT-MSCs) following debridement and lavage arthroscopy in patients with early-stage knee OA. Study Design: Cohort study; Level of evidence, 3. Methods: This retrospective study included 225 patients with Kellgren-Lawrence grade I-II knee OA treated with either UCD-PRP ( Results: Both groups showed significant functional and pain improvements from baseline at all follow-up points. The UCD-PRP group demonstrated superior pain reduction on VAS at 3 and 6 months compared with ADT-MSCs (ΔVAS at 3 months, Conclusion: UCD-PRP provides superior short-term pain relief compared with ADT-MSCs following knee arthroscopy for early OA, with comparable functional outcomes at 12 months. Its standardized, allogeneic preparation and minimal donor-site morbidity make UCD-PRP a promising orthobiologic option for knee OA management. Level of Evidence: Level III.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.